Results 91 to 100 of about 58,798 (254)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Departing from standard practices: Strategic application of value engineering in the anatomy laboratory to enhance formaldehyde extraction using high‐impact, low‐cost, and low‐maintenance solutions

Anatomical Sciences Education, Volume 18, Issue 3, Page 241-253, March 2025.
Abstract This study describes the process of developing a high‐impact, low‐cost, and low‐maintenance air ventilation system for anatomy facilities. It employed the strategic application of Value Engineering (VE), assuring that the air ventilation system meets contemporary threshold limit values (TLVs) for formaldehyde in the working zone of dissection ...
Jürgen Russ, Niels Hammer
wiley   +1 more source

Through Parents' Eyes: Perspectives on Child Development and Family Experience During ESDM Intervention

Autism Research, EarlyView.
ABSTRACT Early intensive intervention for autistic children aims to support developmental progress in social and communication domains. Although outcomes are typically assessed using standardized measures of child development, parental perspectives during early intervention remain largely understudied.
Kenza Latrèche, Fiona Journal, Michel Godel, Martina Franchini, Nada Kojovic, David Cimasoni, Marcin Czajkowski, Lucie Delieutraz, Chloé Laubu, Marie Schaer   +9 more
wiley   +1 more source

A Multistate Analysis of Policyholder Behaviour in Life Insurance—Lasso-Based Modelling Approaches

Risks
Holders of life insurance policies can exercise various options that lead to contract modifications, e.g., full surrender, partial surrender, and paid-up and dynamic premium increase options.
Lucas Reck, Johannes Schupp, Andreas Reuß   +2 more
doaj   +1 more source

Joint-Life Insurance Premium Model Using Archimedean Copula: The Study of Mortality in Indonesia

Journal of the Indonesian Mathematical Society
Joint-life insurance pays a sum insured when the first death occurs. This insurance has a case based on the order of exit from the cohort, namely joint life and last survivor. The former means that one of the insured leaves the cohort, while the latter means the last member of the insured has left his or her cohort.
Muhammad Akhirul Ramadhan, Ahmad Fuad Zainuddin, Udjianna Sekteria Pasaribu, RR Kurnia Novita Sari   +3 more
openaire   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Capacity building in medicines development and regulation in Africa—Overview on recent progress

British Journal of Clinical Pharmacology, EarlyView.
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke, Emile Malan, Michael Reid, Patrick Bouic, Haylene Nell, Goonaseelan Pillai, Catriona Waitt, Bernd Rosenkranz   +7 more
wiley   +1 more source

Histogenetic insights and genetic landscape of fibromatosis-like undifferentiated gastric carcinoma: a focused study

World Journal of Surgical Oncology
Background The aim of this study was to elucidate the histogenesis and genetic underpinnings of fibromatosis-like undifferentiated gastric carcinoma (FLUGC), a rare pathological entity.
Yang-Kun Wang, Su-Nan Wang, Xing-Hai Liao, Zhi-Qiang Wang, Ping Li, Tian Yun, De-Qi Meng   +6 more
doaj   +1 more source